Shire's CSO leads tech transformation programme FTSE 100
biopharmaceutical company Shire, led by chief strategy officer Claire Debney and legal strategy manager Ama Zbarcea, has conducted an extensive sandbox exercise to engage its staff in the selection of a contract management system, as part of a much wider technology - led transformation programme.
FTSE 100
biopharmaceutical company Shire, led by director of legal strategy Claire Debney (pictured top left) and legal strategy manager Ama Zbarcea, has conducted an extensive sandbox exercise to engage its staff in the selection of a contract management system, as part of a much wider technologyled transformation programme.
Not exact matches
Shire is a Dublin - based
biopharmaceutical company that researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products.
Press Release:
Shire pays $ 825m to develop Renovo's scar - reduction remedy By Karen Attwood Thursday, 21 June 2007 Share
Shire is to pay up to $ 825m (# 414m) to Renovo for the exclusive development and commercialisation rights to the
biopharmaceutical company's groundbreaking scar - prevention drug.